LOS ANGELES, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CURESHANK, founded in 2019, is a small nonprofit in the Medical Research sector that reported $465K in total revenue in fiscal year 2023. The organization ran a surplus of $177K, a strong 38% operating margin.
TO ACCELERATE THE DEVELOPMENT OF TREATMENTS FOR PHELAN-MCDERMID SYNDROME AND SHANK-RELATED DISORDERS. OUR APPROACH IS TO IDENTIFY AND FUND PROJECTS THAT OVERCOME CRITICAL BARRIERS TO SUCCESSFUL DRUG DEVELOPMENT AND TO COORDINATE SCIENTIFIC EFFORTS TO IMPROVE EFFICIENCY AND SPEED IN THE FIELD.
CURESHANK WILL BRING THE SCIENTIFIC COMMUNITY TOGETHER BY ORGANIZING SCIENTIFIC SYMPOSIA AND OTHER MEETINGS. WITH OUR SCIENTIFIC STAKEHOLDERS, WE WILL DEVELOP A RESEARCH ROADMAP TO A CURE FOR...
CURESHANK WILL BRING THE SCIENTIFIC COMMUNITY TOGETHER BY ORGANIZING SCIENTIFIC SYMPOSIA AND OTHER MEETINGS. WITH OUR SCIENTIFIC STAKEHOLDERS, WE WILL DEVELOP A RESEARCH ROADMAP TO A CURE FOR SHANK-RELATED DISORDERS. WE WILL ALSO SERVE AS AN HONEST BROKER TO ENABLE COLLABORATION AMONG SHANK RESEARCHERS AND COORDINATION OF THEIR PROJECTS TO IMPROVE THE SPEED AND EFFICIENCY OF RESEARCH.
CURESHANK WILL FUND TARGETED RESEARCH STUDIES, INCLUDING SCIENTIFIC PROJECTS THAT ELUCIDATE THE UNDERLYING DISEASE MECHANISMS, THAT IDENTIFY AND VALIDATE TARGETS FOR DRUG DEVELOPMENT, AND THAT...
CURESHANK WILL FUND TARGETED RESEARCH STUDIES, INCLUDING SCIENTIFIC PROJECTS THAT ELUCIDATE THE UNDERLYING DISEASE MECHANISMS, THAT IDENTIFY AND VALIDATE TARGETS FOR DRUG DEVELOPMENT, AND THAT DE-RISK PROMISING DRUG TARGETS. CURESHANK WILL ALSO FUND CERTAIN PROMISING CLINICAL TRIALS READINESS INITIATIVES. THESE ACTIVITIES ARE NEEDED TO INCREASE THE NUMBER OF DRUG TARGETS MOVING FROM ACADEMIC RESEARCH LABS INTO SUCCESSFUL INDUSTRY-SPONSORED CLINICAL TRIALS.
CURESHANK WILL ADVOCATE FOR INCREASED FUNDING OF SHANK RESEARCH BY OTHER STAKEHOLDERS AND STRATEGIZE WITH RESEARCHERS ON INITIATIVES, SUCH AS SEED GRANTS, THAT COULD HELP ATTRACT RESEARCH INVESTMENT...
CURESHANK WILL ADVOCATE FOR INCREASED FUNDING OF SHANK RESEARCH BY OTHER STAKEHOLDERS AND STRATEGIZE WITH RESEARCHERS ON INITIATIVES, SUCH AS SEED GRANTS, THAT COULD HELP ATTRACT RESEARCH INVESTMENT BY OTHER FUNDERS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $464,972 | $487,302 | 0.0% |
| Expenses | $287,968 | $219,660 | +0.3% |
| Net Income | $177,004 | $267,642 | -0.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| GERALDINE BLISS | PRESIDENT | 50.00 |
Officer
Director
|
$0 | $0 | $0 |
| PAULINA RYCHENKOVA | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| ABBY LIEVENSE | TREASURER | 15.00 |
Officer
Director
|
$0 | $0 | $0 |
| TALYA EMERY SILVA | VICE PRESIDENT | 35.00 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $464,972 | $287,968 | $1,042,385 | $177,004 |
| 2022 | $487,302 | $219,660 | $854,048 | $267,642 |
| 2021 | $547,552 | $18,174 | $586,406 | $529,378 |
Compare CURESHANK with other nonprofits in California and across the country.